The chimeric protein tyrosine kinase ETV6-NTRK3 requires both Ras-Erk1/2 and PI3-kinase-Akt signaling for fibroblast transformation

Cancer Research

Volumn 61, Issue 24, 2001, Pages 8909-8916

  Tognon, Cristina ^a   Garnett, Mathew ^a   Kenward, Elizabeth ^a   Morrison, Kevin ^a   Sorensen, Poul H B ^a   Kay, R ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CHIMERIC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CELL CYCLE; CELL TRANSFORMATION; COLONY FORMATION; ENZYME ACTIVATION; ENZYME INHIBITION; FIBROBLAST; GENE EXPRESSION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; 3T3 CELLS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CYCLIN D1; DNA-BINDING PROTEINS; ENZYME ACTIVATION; ENZYME INHIBITORS; MAP KINASE KINASE 1; MAP KINASE SIGNALING SYSTEM; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-ETS; RAS PROTEINS; RECEPTOR, TRKC; RECOMBINANT FUSION PROTEINS; REPRESSOR PROTEINS; SIGNAL TRANSDUCTION;

EID: 0035893926     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma
2. Other soft tissue sarcomas of childhood
3. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma
4. Congenital mesoblastic nephroma t(12;15) is associated with ETV6-NTRK3 gene fusion: Cytogenetic and molecular relationship to congenital (infantile) fibrosarcoma
5. Fibromatosis and fibrosarcoma in infancy and childhood
6. Renal tumors
7. ETV6-NTRK3 gene fusion in metastasizing congenital fibrosarcoma
8. The ETS-related factor TEL is regulated by angiogenic growth factor VEGF in HUVE-cells
9. The TEL/ETV6 gene is required specifically for hematopoiesis in the bone marrow
10. Fusion of PDGF receptor β to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation
11. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia
12. The t(12:21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion
13. TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia
14. A new ETV6/TEL partner gene, ARG (ABL-related gene or ABL2), identified in an AML-M3 cell line with a t(l;12)(q25;p13) translocation
15. The role of chromosome translocations in leukemogenesis
16. Fusion of ETV6 to neurotrophin-3 receptor TRKC in acute myeloid leukemia with t(12;15)(p13;q25)
17. Neurotrophin signal transduction in the nervous system
18. Tissue-specific expression of the human tropomyosin gene involved in the generation of the trk oncogene
19. High frequency of activation of tyrosine kinase oncogenes in human papillary thyroid carcinoma
20. Neurotrophin receptors, tumor progression and tumor maturation
21. Neurotrophins, and Trk receptors in human pancreatic ductal adenocarcinoma: Expression patterns and effects on in vitro invasive behavior
22. Identification and characterization of an activating TrkA deletion mutation in acute myeloid leukemia
23. Rational basis for trk inhibition therapy for prostate cancer
24. The ETV6-NTRK3 gene fusion encodes a chimeric protein tyrosine kinase that transforms NIH3T3 cells
25. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia
26. Nerve growth factor induced stimulation of Ras requires Trk interaction with Shc but does not involve phosphoinositide 3-OH kinase
27. TrkB and TrkC neurotrophin receptors cooperate in promoting survival of hippocampal and cerebellar granule neurons
28. Versatile retroviral vectors for potential use in gene therapy
29. Production of high-titer helper-free retroviruses by transient transfection
30. Association of the Abl tyrosine kinase with the Trk nerve growth factor receptor
31. SH2-B is required for nerve growth factor-induced neuronal differentiation
32. Down-regulation of epidermal growth factor receptors by nerve growth factor in PC12 cells is p140(trk)-, Ras-, and Src-dependent
33. Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein
34. 1 phase cell cycle machinery
35. Protein kinases: Six degrees of separation?
36. A synthetic inhibitor of the mitogen-activated protein kinase cascade
37. Wortmannin, a potent and selective inhibitor of phosphatidylinositol-3- kinase
38. Residues crucial for Ras interaction with GDP-GTP exchangers
39. Suppression of Raf-1 kinase activity and MAP kinase signaling by RKIP
40. Regulation of neuronal survival by the serine-threonine protein kinase Akt
41. P13K: Downstream AKTion blocks apoptosis
42. K252a is a selective inhibitor of the tyrosine protein kinase activity of the trk family of oncogenes and neurotrophin receptors
43. Cyclin D expression is controlled post-transcriptionally via a phosphatidylinositol 3-kinase/Akt-dependent pathway
44. GEFs: Structural basis for their activation of small GTP-binding proteins
45. Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells
46. Transformation of mammalian cells by constitutively active MAP kinase kinase
47. Hyperexpression of mitogen-activated protein kinase in human breast cancer
48. Activation of mitogen-activated protein kinase associated with prostate cancer progression
49. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo
50. Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas
51. Identification and characterization of a new oncogene derived from the regulatory subunit of phosphoinositide 3-kinase
52. PIK3CA is implicated as an oncogene in ovarian cancer
53. The multiple roles of PTEN in tumor suppression
54. Targets of oncogenes and tumor suppressors: Key for understanding basic mechanisms of carcinogenesis
55. R-Ras can activate the phosphoinositide 3-kinase but not the MAP kinase arm of the Ras effector pathways
56. Akt/PKB activity is required for Ha-Ras-mediated transformation of intestinal epithelial cells
57. Phosphorylation and regulation of Raf by Akt (protein kinase B)
58. Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt
59. Apoptosis suppression by Raf-1 and MEK 1 requires MEK-and phosphatidylinositol 3-kinase-dependent signals
60. Pancreatic tumor cells with mutant K-ras suppress ERK activity by MEK-dependent induction of MAP kinase phosphatase-2
61. 1 progression in NIH 3T3 cells
62. 1 cyclin-dependent kinases are sufficient to initiate DNA synthesis in quiescent human fibroblasts
63. Ras activity and cyclin D1 expression: An essential mechanism of mouse skin tumor development
64. Reduced skin tumor development in cyclin D1-deficient mice highlights the oncogenic ras pathway in vivo
65. Activated MEK stimulates expression of AP-1 components independently of phosphatidylinosjitol 3-kinase (PI3-kinase) but requires a PI3-kinase signal to stimulate DNA synthesis
66. Multiple ras effector pathways contribute to G(I) cell cycle progression
67. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
68. Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization
69. The MEK inhibitor, PD98059, reduces survival but does not block acute myeloid leukemia blast maturation in vitro